122 related articles for article (PubMed ID: 16041009)
1. Prevention and treatment of cutaneous leishmaniasis in primates by using synthetic type D/A oligodeoxynucleotides expressing CpG motifs.
Flynn B; Wang V; Sacks DL; Seder RA; Verthelyi D
Infect Immun; 2005 Aug; 73(8):4948-54. PubMed ID: 16041009
[TBL] [Abstract][Full Text] [Related]
2. Use of thermolytic protective groups to prevent G-tetrad formation in CpG ODN type D: structural studies and immunomodulatory activity in primates.
Puig M; Grajkowski A; Boczkowska M; Ausín C; Beaucage SL; Verthelyi D
Nucleic Acids Res; 2006; 34(22):6488-95. PubMed ID: 17130156
[TBL] [Abstract][Full Text] [Related]
3. CpG oligodeoxynucleotides as vaccine adjuvants in primates.
Verthelyi D; Kenney RT; Seder RA; Gam AA; Friedag B; Klinman DM
J Immunol; 2002 Feb; 168(4):1659-63. PubMed ID: 11823494
[TBL] [Abstract][Full Text] [Related]
4. CpG oligodeoxynucleotides protect normal and SIV-infected macaques from Leishmania infection.
Verthelyi D; Gursel M; Kenney RT; Lifson JD; Liu S; Mican J; Klinman DM
J Immunol; 2003 May; 170(9):4717-23. PubMed ID: 12707351
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
[TBL] [Abstract][Full Text] [Related]
6. The role of liposome-protamine-DNA nanoparticles containing CpG oligodeoxynucleotides in the course of infection induced by Leishmania major in BALB/c mice.
Alavizadeh SH; Badiee A; Khamesipour A; Jalali SA; Firouzmand H; Abbasi A; Jaafari MR
Exp Parasitol; 2012 Nov; 132(3):313-9. PubMed ID: 22819791
[TBL] [Abstract][Full Text] [Related]
7. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis.
Zimmermann S; Egeter O; Hausmann S; Lipford GB; Röcken M; Wagner H; Heeg K
J Immunol; 1998 Apr; 160(8):3627-30. PubMed ID: 9558060
[TBL] [Abstract][Full Text] [Related]
8. Alginate microspheres encapsulated with autoclaved Leishmania major (ALM) and CpG-ODN induced partial protection and enhanced immune response against murine model of leishmaniasis.
Tafaghodi M; Eskandari M; Khamesipour A; Jaafari MR
Exp Parasitol; 2011 Oct; 129(2):107-14. PubMed ID: 21767536
[TBL] [Abstract][Full Text] [Related]
9. Contribution of human neutrophils in the development of protective immune response during in vitro Leishmania major infection.
Safaiyan S; Bolhassani A; Nylen S; Akuffo H; Rafati S
Parasite Immunol; 2011 Nov; 33(11):609-20. PubMed ID: 21793857
[TBL] [Abstract][Full Text] [Related]
10. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.
Mendez S; Tabbara K; Belkaid Y; Bertholet S; Verthelyi D; Klinman D; Seder RA; Sacks DL
Infect Immun; 2003 Sep; 71(9):5121-9. PubMed ID: 12933855
[TBL] [Abstract][Full Text] [Related]
11. Dendritic cells are responsible for the capacity of CpG oligodeoxynucleotides to act as an adjuvant for protective vaccine immunity against Leishmania major in mice.
Shah JA; Darrah PA; Ambrozak DR; Turon TN; Mendez S; Kirman J; Wu CY; Glaichenhaus N; Seder RA
J Exp Med; 2003 Jul; 198(2):281-91. PubMed ID: 12874261
[TBL] [Abstract][Full Text] [Related]
12. CpG oligonucleotides as adjuvant in therapeutic vaccines against parasitic infections.
Zimmermann S; Dalpke A; Heeg K
Int J Med Microbiol; 2008 Jan; 298(1-2):39-44. PubMed ID: 17716944
[TBL] [Abstract][Full Text] [Related]
13. Immunoregulatory activity of CpG oligonucleotides in humans and nonhuman primates.
Verthelyi D; Klinman DM
Clin Immunol; 2003 Oct; 109(1):64-71. PubMed ID: 14585277
[TBL] [Abstract][Full Text] [Related]
14. Inhibition of the hepatitis B virus replication in vitro by an oligodeoxynucleotide containing cytidine-guanosine motifs.
Li N; Fan XG; Chen ZH; Zhu C; Liu HB; Huang Y
Immunol Lett; 2006 Jan; 102(1):60-6. PubMed ID: 16105691
[TBL] [Abstract][Full Text] [Related]
15. Targeting of immunostimulatory DNA cures experimental visceral leishmaniasis through nitric oxide up-regulation and T cell activation.
Datta N; Mukherjee S; Das L; Das PK
Eur J Immunol; 2003 Jun; 33(6):1508-18. PubMed ID: 12778468
[TBL] [Abstract][Full Text] [Related]
16. [Toll-like receptor 9 in cpG oligodeoxynucleotides-induced species-specific immune responses].
Li N; Fan XG; Tang SE; Zhu C
Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2005 Oct; 30(5):533-5. PubMed ID: 16320582
[TBL] [Abstract][Full Text] [Related]
17. Parameters of CpG oligodeoxynucleotide-induced protection against intravaginal HSV-2 challenge.
Sajic D; Ashkar AA; Patrick AJ; McCluskie MJ; Davis HL; Levine KL; Holl R; Rosenthal KL
J Med Virol; 2003 Dec; 71(4):561-8. PubMed ID: 14556270
[TBL] [Abstract][Full Text] [Related]
18. Immunostimulatory oligodeoxynucleotides are potent enhancers of protective immunity in mice immunized with recombinant ORFF leishmanial antigen.
Tewary P; Sukumaran B; Saxena S; Madhubala R
Vaccine; 2004 Aug; 22(23-24):3053-60. PubMed ID: 15297055
[TBL] [Abstract][Full Text] [Related]
19. CpG oligonucleotides accelerate and boost the immune response elicited by AVA, the licensed anthrax vaccine.
Klinman DM
Expert Rev Vaccines; 2006 Jun; 5(3):365-9. PubMed ID: 16827620
[TBL] [Abstract][Full Text] [Related]
20. Differential and competitive activation of human immune cells by distinct classes of CpG oligodeoxynucleotide.
Gürsel M; Verthelyi D; Gürsel I; Ishii KJ; Klinman DM
J Leukoc Biol; 2002 May; 71(5):813-20. PubMed ID: 11994506
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
